Compare Invesco Ltd. (IVZ) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Ltd. vs Tango Therapeutics Inc. — how do they compare? Invesco Ltd. trades at $27.87 (market cap $12.77B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Invesco Ltd. is far larger — about 3.4× Tango Therapeutics Inc.'s market cap, and Invesco Ltd. pays a 2.97% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Ltd. for 77 Days and Tango Therapeutics Inc. for 0 Days on average.
| IVZ | TNGX | |
|---|---|---|
Market Cap | $12.77B | $3.75B |
Volume | 2,758,656 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $33.31 | $32.90 |
52-Week Low | $22.44 | $7.50 |
Typical Hold Time | 77 Days | 0 Days |
Enterprise Value | $22.93B | $2.77B |
Dividend Yield | 2.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Invesco (IVZ) trades at $27.93, down 4.55% on the day, with a bearish technical signal and mixed earnings history. The company reported a net loss of $281.70 million in 2025 despite revenue growth to $6.38 billion, with a negative net income margin of -0.93%. Recent news highlights product expansions, including the launch of the Invesco Nasdaq International Innovators 100 ETF, and a dividend of $0.22 per share scheduled for September 2026.
The outlook is cautious; analyst consensus is a buy with a $33.17 price target, but profitability challenges and bearish technicals pose risks. Positive cash flow and AUM growth offer potential, yet investors must weigh weak margins against strategic initiatives in a competitive ETF landscape.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
